BACKGROUND Venous thromboembolism (VTE) is a frequent and potentially costly complication of major orthopedic surgery. OBJECTIVE To estimate the economic consequences of VTE following major orthopedic surgery. METHODS Using a large healthcare claims database, we identified all patients who underwent total hip replacement, major knee surgery, or hip fracture repair from January 1993 to December 1998. Patients with clinical VTE (cases) were identified based on a diagnosis of deep vein thrombosis or pulmonary embolism within 90 days of surgery (index admission) and ≥1 prescription for warfarin or unfractionated heparin within 30 days of the date of initial VTE diagnosis. Each case was matched (using age and procedure type) to 2 randomly selected patients who did not have any claims for clinical VTE (matched controls). Utilization and billed charges were then examined over a 90-day period following admission. Cases were stratified based on whether VTE was first noted during the index admission or thereafter. RESULTS A total of 11 960 patients were identified who underwent total hip replacement, major knee surgery, or hip fracture repair (n = 3171, 3955, 4834, respectively). Over a 90-day period, 259 patients (2.2%) developed clinical VTE. Most cases (61.8%) occurred after hospital discharge. For patients with in-hospital VTE, mean length of stay for the index admission was 4.5 days longer than that of matched controls (11.1 vs 6.6); by day 90, there was a 5.4-day difference in total hospital days. Mean billed charges for the index admission were $17 552 higher ($52 037 vs $34 485); the difference rose to $18 834 by day 90 ($54 480 vs $35 646). For patients who developed clinical VTE following hospital discharge, there was a 3.4-day difference in total hospital days at day 90 (10.2 vs 6.8) as a result of readmissions for VTE; mean total billed charges at day 90 were $5765 higher ($41 411 vs $35 646) CONCLUSION Among patients who have undergone major orthopedic surgery, the economic consequences of VTE are substantial, regardless of the setting in which it occurs.
[1]
G. Oster,et al.
Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients.
,
2002,
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[2]
R. Friedman,et al.
Cost Analyses of Extended Prophylaxis With Enoxaparin After Hip Arthroplasty
,
2000,
Clinical orthopaedics and related research.
[3]
C. Colwell,et al.
Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.
,
1999,
The Journal of bone and joint surgery. American volume.
[4]
W. Bargar,et al.
Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty.
,
1998,
Archives of internal medicine.
[5]
J. Hirsh,et al.
The Incidence of Symptomatic Venous Thromboembolism During and After Prophylaxis With Enoxaparin: A Multi-institutional Cohort Study of Patients Who Underwent Hip or Knee Arthroplasty
,
1998
.
[6]
G. Oster,et al.
Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
,
1995,
Archives of internal medicine.
[7]
M. McNally,et al.
Postphlebitic syndrome after hip arthroplasty. 43 patients followed at least 5 years.
,
1994,
Acta orthopaedica Scandinavica.
[8]
D. Haake,et al.
Venous thromboembolic disease after hip surgery. Risk factors, prophylaxis, and diagnosis.
,
1989,
Clinical orthopaedics and related research.
[9]
J. Heit,et al.
Prevention of venous thromboembolism.
,
1995,
Chest.
[10]
G. Lowe.
Epidemiology of postoperative deep vein thrombosis and pulmonary embolism.
,
1991,
Seminars in thrombosis and hemostasis.